Crown Bioscience is set to display significant advances in preclinical and translational oncology research at a prominent cancer research meeting, AACR 2024. The company's contributions to the cont...
With this approval, the MEBGEN™ BRAF 2 Kit is expected to contribute to the timely personalized treatment for patients with radically unresectable thyroid cancer based on the presence or absence of...